GHRS
GH Research PLC
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Neutral
-14/100
Last price
21.12
▼ 0.40 (1.86%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
21.39
Prev close
21.52
Day high
22.17
Day low
21.03
Volume
70.56K
Market cap
$1.45B
P/E (TTM)
—
52W range
12.04 – 31.44
Day trading desk
Gap from prior close
-0.60%
Prior close 21.52
VWAP
21.48
-1.69% from price
Relative volume
0.22×
Quiet session
Session range
5.42%
21.03 – 22.17
Position in range
8%
Near session low
ATR (14D)
1.36
6.43% of price
Prior day high
22.27
PDH
Prior day low
21.21
PDL
Bid / ask spread
—
Quote not published
Session volume
64.21K
Avg 295.05K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-10.05%
-11.8%
1M
-24.00%
-25.4%
3M
-22.35%
-25.6%
6M
+40.89%
+26.1%
YTD
+66.30%
+52.5%
1Y
+61.72%
+46.1%
3Y
+104.85%
+23.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on GHRS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
16.79M
Total on file
Fundamentals
Market cap$1.45B
Enterprise value$1.11B
Revenue (TTM)—
Gross profit—
EBITDA$-71.33M
Net income$-62.27M
EPS (TTM)$-0.99
Free cash flow$-36.52M
Total cash$362.65M
Total debt$360.00K
Book value / share$5.24
Shares outstanding68.64M
Float32.37M
Short % of float10.04%
Dividend yield0.00%
Beta (5Y)1.33
Valuation & profitability ratios
Trailing P/E—
Forward P/E-11.42
PEG ratio—
Price / sales—
Price / book4.03
EV / revenue—
EV / EBITDA-15.63
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-18.79%
Return on assets-13.02%
Debt / equity0.10
Current ratio28.70
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $38.77M | $35.02M | $29.82M | $20.48M | +10.7% |
| Selling, general & admin | $21.65M | $15.00M | $11.12M | $10.06M | +44.3% |
| Total operating expense | $60.68M | $50.25M | $41.22M | $30.68M | +20.8% |
| Operating income | -$60.68M | -$50.25M | -$41.22M | -$30.68M | -20.8% |
| Net interest income | $4.62M | $5.56M | $5.30M | $735.00K | -16.9% |
| Pre-tax income | -$48.26M | -$38.96M | -$35.59M | -$22.46M | -23.9% |
| Tax provision | $0 | $0 | $0 | $0 | — |
| Net income | -$48.26M | -$38.96M | -$35.59M | -$22.46M | -23.9% |
| Net income to common | -$48.26M | -$38.96M | -$35.59M | -$22.46M | -23.9% |
| Basic EPS | -0.79 | -0.75 | -0.68 | -0.43 | -5.3% |
| Diluted EPS | -0.79 | -0.75 | -0.68 | -0.43 | -5.3% |
| EBIT | -$48.22M | -$38.91M | -$35.52M | -$22.46M | -23.9% |
| EBITDA | -$47.89M | -$38.60M | -$35.21M | -$22.41M | -24.1% |
| Basic shares | 61.04M | 51.95M | 52.33M | 52.02M | +17.5% |
| Diluted shares | 61.04M | 51.95M | 52.33M | 52.02M | +17.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $246.25M | $100.79M | $78.42M | $165.96M | +144.3% |
| Cash & short-term investments | $280.71M | $149.32M | $161.56M | $165.96M | +88.0% |
| Total current assets | $285.98M | $154.22M | $164.09M | $168.54M | +85.4% |
| Property, plant & equipment | $620.00K | $748.00K | $1.07M | $97.00K | -17.1% |
| Total assets | $288.23M | $188.27M | $226.30M | $254.36M | +53.1% |
| Total current liabilities | $8.38M | $8.95M | $6.70M | $4.55M | -6.4% |
| Total debt | $512.00K | $624.00K | $974.00K | $0 | -17.9% |
| Total liabilities | $8.53M | $9.32M | $7.33M | $4.55M | -8.5% |
| Retained earnings | -$154.43M | -$106.45M | -$67.94M | -$32.49M | -45.1% |
| Shareholder equity | $279.70M | $178.95M | $218.97M | $249.82M | +56.3% |
| Working capital | $277.60M | $145.27M | $157.39M | $164.00M | +91.1% |
| Net tangible assets | $279.70M | $178.95M | $218.97M | $249.82M | +56.3% |
| Shares issued | 62.03M | 52.03M | 52.03M | 52.02M | +19.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$48.26M | -$38.96M | -$35.59M | -$22.46M | -23.9% |
| Depreciation & amortisation | $335.00K | $315.00K | $315.00K | $47.00K | +6.3% |
| Stock-based compensation | $8.50M | $1.17M | $2.29M | $1.67M | +626.2% |
| Change in working capital | -$3.09M | $188.00K | $1.65M | $2.16M | -1,745.7% |
| Operating cash flow | -$43.55M | -$42.28M | -$33.34M | -$26.20M | -3.0% |
| Capital expenditure | -$121.00K | -$49.00K | -$100.00K | -$67.00K | -146.9% |
| Investing cash flow | $46.17M | $65.14M | -$54.10M | -$84.69M | -29.1% |
| Financing cash flow | $139.65M | -$304.00K | -$204.00K | $0 | +46,037.8% |
| Free cash flow | -$43.67M | -$42.33M | -$33.44M | -$26.27M | -3.2% |
| End cash position | $246.25M | $100.79M | $78.42M | $165.96M | +144.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $12.40M | $12.38M | $11.39M | $10.57M | $8.96M | — | +0.2% |
| Selling, general & admin | $7.06M | $6.37M | $5.25M | $5.92M | $5.75M | — | +10.8% |
| Total operating expense | $19.45M | $18.75M | $16.70M | $16.54M | $14.69M | — | +3.7% |
| Operating income | -$19.45M | -$18.75M | -$16.70M | -$16.54M | -$14.69M | — | -3.7% |
| Net interest income | $966.00K | $582.00K | $722.00K | $980.00K | $1.08M | — | +66.0% |
| Pre-tax income | -$15.15M | -$18.97M | -$14.14M | -$14.02M | -$9.29M | — | +20.1% |
| Tax provision | $0 | $0 | $0 | $0 | $0 | — | — |
| Net income | -$15.15M | -$18.97M | -$14.14M | -$14.02M | -$9.29M | — | +20.1% |
| Net income to common | -$15.15M | -$18.97M | -$14.14M | -$14.02M | -$9.29M | — | +20.1% |
| Basic EPS | -0.23 | -0.31 | — | -0.23 | -0.15 | -0.19 | +25.8% |
| Diluted EPS | -0.23 | -0.31 | — | -0.23 | -0.15 | -0.19 | +25.8% |
| EBIT | -$15.14M | -$18.96M | -$14.13M | -$14.01M | -$9.28M | — | +20.2% |
| EBITDA | -$15.05M | -$18.87M | -$14.04M | -$13.92M | -$9.20M | — | +20.2% |
| Basic shares | 66.53M | 62.03M | — | 62.03M | 62.03M | 58.03M | +7.3% |
| Diluted shares | 66.53M | 62.03M | — | 62.03M | 62.03M | 58.03M | +7.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $345.05M | $242.65M | $246.25M | $249.65M | $253.87M | +42.2% |
| Cash & short-term investments | $362.65M | $267.32M | $280.71M | $288.51M | $291.54M | +35.7% |
| Total current assets | $368.82M | $272.23M | $285.98M | $294.79M | $293.88M | +35.5% |
| Property, plant & equipment | $502.00K | $580.00K | $620.00K | $692.00K | $739.00K | -13.4% |
| Total assets | $372.35M | $275.27M | $288.23M | $302.02M | $313.43M | +35.3% |
| Total current liabilities | $12.85M | $11.81M | $8.38M | $10.41M | $9.97M | +8.8% |
| Total debt | $360.00K | $432.00K | $512.00K | $582.00K | $647.00K | -16.7% |
| Total liabilities | $12.86M | $11.89M | $8.53M | $10.63M | $10.25M | +8.1% |
| Retained earnings | -$187.84M | -$173.23M | -$154.43M | -$140.29M | -$126.27M | -8.4% |
| Shareholder equity | $359.49M | $263.38M | $279.70M | $291.40M | $303.18M | +36.5% |
| Working capital | $355.97M | $260.42M | $277.60M | $284.38M | $283.91M | +36.7% |
| Net tangible assets | $359.49M | $263.38M | $279.70M | $291.40M | $303.18M | +36.5% |
| Shares issued | 68.64M | 62.05M | 62.03M | 62.03M | 62.03M | +10.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$15.15M | -$18.97M | -$14.14M | -$14.02M | -$9.29M | +20.1% |
| Depreciation & amortisation | $91.00K | $91.00K | $88.00K | $89.00K | $82.00K | 0.0% |
| Stock-based compensation | $2.16M | $1.83M | $2.66M | $2.33M | $1.88M | +18.0% |
| Change in working capital | -$845.00K | $2.96M | -$1.56M | -$2.90M | $1.16M | -128.5% |
| Operating cash flow | -$15.02M | -$10.67M | -$12.33M | -$13.68M | -$8.97M | -40.8% |
| Capital expenditure | -$17.00K | -$63.00K | -$19.00K | -$39.00K | -$59.00K | +73.0% |
| Investing cash flow | $6.34M | $8.64M | $8.84M | $9.78M | $15.71M | -26.5% |
| Financing cash flow | $111.87M | $2.00K | -$68.00K | -$66.00K | -$1.07M | +5,593,300.0% |
| Free cash flow | -$15.04M | -$10.73M | -$12.35M | -$13.72M | -$9.03M | -40.1% |
| End cash position | $345.05M | $242.65M | $246.25M | $249.65M | $253.87M | +42.2% |
Options analytics
Put / call volume
0.77
Call-heavy session
Put / call open interest
1.75
Positioning, not flow
Max pain
25.00
+18.4% from spot
ATM implied vol
12.5%
Nearest strike to spot
Skew (10% OTM)
+58.1%
Puts bid over calls
Call volume
26
Contracts, this expiry
Put volume
20
Contracts, this expiry
Heaviest call OI
25.00
34 contracts
Heaviest put OI
20.00
134 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.30 | -0.23 | +24.2% |
| Mar 2026 | -0.26 | -0.31 | -17.7% |
| Dec 2025 | -0.27 | -0.22 | +19.4% |
| Sep 2025 | -0.23 | -0.23 | -1.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.30 | 9 | $0 | 0.0% |
| Next quarter | -0.35 | 9 | $0 | 0.0% |
| Current year | -1.17 | 9 | $0 | 0.0% |
| Next year | -1.85 | 9 | $0 | 0.0% |
Analyst targets & ownership
Mean target$42.89
High target$65.00
Low target$38.00
Implied upside103.07%
Analyst count9
ConsensusNONE
Strong buy / Buy2 / 7
Hold0
Sell / Strong sell0 / 0
Held by insiders24.46%
Held by institutions71.44%
Institutions holding88
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
23.05
-8.36% from price
SMA 20
25.34
-16.67% from price
SMA 50
27.36
-22.82% from price
SMA 100
25.96
-18.63% from price
SMA 200
21.10
+0.10% from price
EMA 12
23.51
-10.18% from price
EMA 26
25.17
-16.08% from price
EMA 50
25.98
-18.72% from price
RSI (14)
25.2
Oversold
MACD (12,26,9)
-1.65
Hist -0.45
ATR (14)
1.36
6.43% of price
Realised vol 30D
41.4%
Annualised
Bollinger upper
30.30
20, 2σ
Bollinger lower
20.39
20, 2σ
50 / 200 cross
Golden
27.36 vs 21.10
Trend bias
Above 200
+0.10%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.43
More volatile than market
Correlation to SPY
0.26
Largely independent
Realised vol 30D
41.4%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-31.1%
Peak to trough
Max drawdown 5Y
-81.1%
Peak to trough
ATR 14
1.36
6.43% of price
Beta (reported)
1.33
5Y monthly, from filing
Short interest
Shares short
2.70M
Prior 3.14M
Change vs prior
-14.1%
Shorts covering
% of float
10.04%
Elevated
% of shares out
3.94%
Against total outstanding
Days to cover
15.1
Crowded exit
Float
32.37M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 7, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Aug 7, 26 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Aug 6, 26 | Needham | MAINTAINED | Buy | Buy |
| Jul 27, 26 | Wells Fargo | INITIATED | — | Overweight |
| May 19, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 15, 26 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| May 15, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Mar 6, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Mar 6, 26 | Needham | MAINTAINED | Buy | Buy |
| Mar 2, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jan 23, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Jan 6, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-09-11
Corporate Changes & Voting Matters
6-K · 2026-08-06
Corporate Changes & Voting Matters
6-K · 2026-06-26
Corporate Changes & Voting Matters
6-K · 2026-06-04
Corporate Changes & Voting Matters
6-K · 2026-05-21
A correspondence can be sent as a document with another submission type or can be sent as a separate submission
CORRESP · 2026-05-15
Corporate Changes & Voting Matters
6-K · 2026-05-14
Corporate Changes & Voting Matters
6-K · 2026-05-13
Headlines
Postpartum Depression Market to Evolve During the Forecast Period (2026-2036) with Breakthrough Treatments and Expanding Pipeline Assets | DelveInsight
PR Newswire · 43d ago
GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update
GlobeNewswire · 62d ago
Is GH Research (GHRS) Trading At A Premium To Fair Value?
Simply Wall St. · 66d ago
CMPS, MDGL, DFTX, GHRS, HELP Stocks In Spotlight Today – Why Wells Fargo Thinks Next Wave Of Depression Drugs Could Create New Winners
Stocktwits · 72d ago
Wells Fargo Initiates GH Research at Overweight With $44 Price Target
MT Newswires · 72d ago
Eli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drug
24/7 Wall St. · 83d ago
Why Psychedelic stocks are surging today
Investing.com · 83d ago
GH Research gains on optimism surrounding potential Eli Lilly-Atai deal (GHRS)
InvestorsHub · 83d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.